47,266 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Talbot Financial LLC

Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 47,266 shares of the company's stock, valued at approximately $4,066,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Novare Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock worth $325,000 after purchasing an additional 85 shares during the period. Steel Grove Capital Advisors LLC increased its stake in shares of Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after acquiring an additional 86 shares during the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Novo Nordisk A/S by 2.6% during the second quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock worth $493,000 after acquiring an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton increased its position in Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock worth $454,000 after purchasing an additional 94 shares during the last quarter. Finally, Burns J W & Co. Inc. NY raised its stake in shares of Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company's stock worth $647,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $140.20.

Novo Nordisk A/S Trading Down 2.1 %

NVO traded down $1.83 during mid-day trading on Monday, reaching $84.43. The stock had a trading volume of 7,408,340 shares, compared to its average volume of 7,408,285. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15. The stock has a market capitalization of $378.88 billion, a P/E ratio of 27.32, a P/E/G ratio of 1.37 and a beta of 0.45. The firm's fifty day simple moving average is $99.84 and its two-hundred day simple moving average is $118.61.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.